Neuralstem Inc. (CUR)
Symbol Info
Listed Symbol CUR
Name Neuralstem Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $260,000
Latest Fiscal EPS $-6.40
Price Info
21 Day Moving Average $2.7583
21 Day EMA $2.958010
50 Day Moving Average $5.1743
50 Day EMA $4.751390
200 Day EMA $9.897740
200 Day Moving Average 8.312020
52 Week High $27.40
52 Week Low $1.62
52 Week Change $-92.288100
Alpha -0.076832
Beta 1.7986
Standard Deviation 0.241918
R2 0.066540
Periods 60
Share Information
10 Day Average Volume 64,612
20 Day Average Volume 183,011
30 Day Average Volume 158,219
50 Day Average Volume 98,587
Outstanding Shares 2,100,291
Float Shares -
Percent Float -
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 43
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 6,633
Institute Holdings Percent 6.000000
Institute Sold Previous 3 Months 1,433,959
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 3,145,370
Price Change
7 Day Price Change $-0.33
7 Day Percent Change -15.35%
21 Day Price Change $-0.5700001
21 Day Percent Change -23.85%
30 Day Price Change $-5.134
30 Day Percent Change -73.83%
Month To Date Price Change $-0.38
Month To Date Percent -17.27%
90 Day Price Change $-7.39
90 Day Percent Change -80.24%
Quarter To Date $-4.06
Quarter To Date Percent -69.05%
180 Day Price Change $-9.230001
180 Day Percent Change -83.53%
200 Day Price Change $-5.8296
200 Day Percent Change -76.21%
Year To Date $-4.442
Year To Date Percent -70.94%
Profile
Description Neuralstem Inc is a clinical-stage biopharmaceutical company. The company is engaged in research, development, and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. Its technology base has produced three primary assets: NSI-189 small molecule program, NSI-566 stem cell therapy program and novel and proprietary new chemical entity screening platform.
Details
Issue Type CS
Market Cap $3,822,530
Sec Type EQS
Auditor Dixon Hughes Goodman LLP
Total Shares Outstanding 2,100,291
CEO Kenneth C. Carter
Employees 5
Last Audit UE
Classification
CIK 0001357459
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 20271 Goldenrod Lane
Germantown, MD 20876
Website http://www.neuralstem.com
Facisimile
Telephone +1 301 366-4841
Email
Key Ratios
Profitability
EBIT Margin -43,484.4
EBITDA Margin -42,518.8
Pre-Tax Profit Margin -91,693.4
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $7,500
Revenue Per Share $0.0036
Revenue 3 Years $113.51
Revenue 5 Years $65.95
Valuation Measures
PE Ratio -
Enterprise Value $1,357,433
Price To Sales 509.670620
Price To Free Cash -0.7
PE High Last 5 Years -
Price To Book 1.9
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.4
Financial Strength
Total Debt To Equity -
Int Coverage -889
Current Ratio 2.5
Leverage Ratio 1.5
Quick Ratio 2.3
Long Term Debt To Capital -
Assets
Receivables Turnover 0.1
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -107.03
Return On Equity -168.23
Return On Capital -166.83
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
CUR
Neuralstem
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.